Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Concert Pharmaceuticals Inc Market Cap
From what 5 stock analysts predict, the share price for Concert Pharmaceuticals Inc (CNCE) might increase by 55.32% in the next year. This is based on a 12-month average estimation for CNCE. Price targets go from $9 to $17. The majority of stock analysts believe CNCE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedCNCE 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Concert Pharmaceuticals Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CNCE. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CNCE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sean Kim JonesTrading | Hold | Downgrade | Jan 20, 2023 | |
| Joon Lee Truist Securities | Buy | $25 | Maintains | Sep 13, 2022 |
| Sean Kim JonesTrading | Buy | $17 | Initiates | Aug 25, 2022 |
| Difei Yang Mizuho | Buy | $9 | Maintains | Oct 5, 2021 |
| Joon Lee Truist Securities | Buy | $22 | Maintains | Feb 2, 2021 |
Berenberg | Buy | Initiates | Dec 16, 2020 | |
HC Wainwright & Co. | Buy | $25 | Reiterates | Oct 3, 2019 |
H.C. Wainwright | Buy | Reiterates | Oct 3, 2019 | |
Mizuho | Buy | $18 | Maintains | Sep 30, 2019 |
SunTrust Robinson Humphrey | Buy | $20 | Maintains | Sep 30, 2019 |
Mizuho | Buy | $29 | Maintains | Sep 4, 2019 |
SunTrust Robinson Humphrey | Buy | Initiates | Jun 24, 2019 | |
Janney Capital | Buy | Upgrade | Jun 13, 2019 | |
Janney Montgomery Scott | Buy | Upgrade | Jun 13, 2019 | |
UBS | Buy | $13 | Maintains | Apr 10, 2019 |
Stifel | Buy | $18 | Maintains | Apr 9, 2019 |
| Difei Yang Mizuho | Buy | $23 | Maintains | Apr 9, 2019 |
Stifel Nicolaus | Buy | Maintains | Apr 9, 2019 | |
Janney Montgomery Scott | Neutral | Initiates | Sep 13, 2018 | |
Janney Capital | Neutral | Initiates | Sep 13, 2018 |
When did it IPO
2014
Staff Count
64
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Roger D. Tung Ph.D.
Market Cap
$401.9M
In 2023, CNCE generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CNCE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 15 Feb 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Concert Pharmaceuticals ($CNCE) retains FDA breakthrough therapy designation for deuruxolitinib, aimed at treating alopecia areata.
Why It Matters - Maintaining breakthrough therapy designation can accelerate deuruxolitinib's market entry, potentially increasing revenue and stock value for Concert Pharmaceuticals.
Thu, 16 Feb 2023
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - Concert Pharmaceuticals, Inc. is a biotech buyout with a negative spread and a contingent value right (CVR) linked to two sales milestones.
Why It Matters - A biotech buyout with a negative spread suggests potential undervaluation. The sales milestone CVR offers additional upside, making it a noteworthy opportunity for profit.
Mon, 13 Feb 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Halper Sadeh LLC is investigating the fairness of Sun Pharmaceutical's $8.00 per share acquisition offer for Concert Pharmaceuticals (NASDAQ: CNCE), with potential additional value of $3.
Why It Matters - The investigation into Concert Pharmaceuticals' sale may signal potential undervaluation, impacting shareholder sentiment and stock price as fairness concerns arise.
Mon, 30 Jan 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Weiss Law is investigating potential fiduciary duty breaches by Evoqua Water Technologies' board regarding its proposed acquisition by Xylem Inc. Investors may contact Weiss Law for inquiries.
Why It Matters - Potential breaches of fiduciary duty during Evoqua's acquisition by Xylem could impact shareholder value, legal outcomes, and the future direction of both companies.
Mon, 23 Jan 2023
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Concert Pharmaceuticals (CNCE) has agreed to be acquired by Sun Pharmaceutical for $576 million. CNCE's stock increased by 17% in the prior week.
Why It Matters - The acquisition boosts investor confidence, reflecting a premium on CNCE's value, while the stock's recent rise indicates positive market sentiment ahead of the deal's completion.
Fri, 20 Jan 2023
Sentiment - POSITIVE
Source - The Motley Fool
Summary - A company is being acquired in a transaction valued at a minimum of $576 million.
Why It Matters - A $576 million acquisition signals potential growth or strategic shifts, affecting stock value and investor sentiment regarding the company's future performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
